81° Sunny

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

117.77 -2.19 (-1.83%)

Streaming Delayed Price Updated: 1:31 PM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Tech Powerhouse: S&P 500 Eyes 12.6% Growth as AI Revolution Enters Second Gear

April 14, 2026

As the first-quarter earnings season of 2026 kicks off, Wall Street is bracing for a high-stakes performance that could determine the trajectory of the market for the remainder of the year. With the...

Via MarketMinute

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Merck & Co. Inc. (NYSE:MRK) Offers a Durable Dividend Backed by Strong Earnings ↗

April 09, 2026

Via Chartmill

1 Profitable Stock for Long-Term Investors and 2 Facing Challenges

April 14, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Via Finterra

Topics Earnings Economy Intellectual Property

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

April 13, 2026

From Daiichi Sankyo

Via Business Wire

1 Momentum Stock on Our Buy List and 2 We Question

April 13, 2026

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

Via StockStory

Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗

April 12, 2026

Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong.

Via The Motley Fool

Topics Intellectual Property

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

Via MarketMinute

Topics Bonds

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Terns Therapeutics, Inc. (Nasdaq – TERN), Whitestone REIT (NYSE – WSR), Rallybio Corporation (Nasdaq – RLYB), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN)

April 09, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue

April 09, 2026

Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall...

Via Finterra

Topics Economy World Trade

Why Terns Pharmaceuticals Stock Rocked the Market in March ↗

April 08, 2026

A large peer is snapping up the company in a premium-priced deal.

Via The Motley Fool

Topics Intellectual Property

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

April 07, 2026

From Merck & Co., Inc.

Via Business Wire

You'll Never Guess Which Healthcare Stock Delivered the Best First-Quarter Performance in the S&P 500. ↗

April 07, 2026

Could this player be heading into a new era of growth?

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

Via MarketMinute

Topics Intellectual Property

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

April 02, 2026

From Merck & Co., Inc.

Via Business Wire

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed...

Via Finterra

Topics Artificial Intelligence Earnings Economy

Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

April 01, 2026

From Merck & Co., Inc.

Via Business Wire

Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility

March 31, 2026

In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500...

Via MarketMinute

Topics Economy Intellectual Property Stocks

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Via Finterra

Topics Initial Public Offering

Merck Just Made a Big Bet on a New Cancer Growth Engine ↗

March 31, 2026

Via MarketBeat

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

March 30, 2026

From Merck & Co., Inc.

Via Business Wire

This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks ↗

March 30, 2026

The Schwab U.S. Dividend Equity ETF is increasing its allocation to healthcare dividend stocks.

Via The Motley Fool

Topics ETFs Stocks

Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

March 29, 2026

From Merck & Co., Inc.

Via Business Wire

1 Reason Eli Lilly Stock Is Still a Buy ↗

March 28, 2026

Eli Lilly is much more than just a weight loss stock.

Via The Motley Fool

Topics Artificial Intelligence

2 Healthcare Stocks That Could Soar Over the Next 5 Years ↗

March 26, 2026

They could make important breakthroughs in their target markets.

Via The Motley Fool

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...

Via MarketMinute

Topics Intellectual Property

ARM Makes Its Move While Wall Street Watches the Strait ↗

March 26, 2026

Via Chartmill

The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind

March 25, 2026

As of March 25, 2026, the global financial markets are witnessing a seismic shift in corporate strategy, marking the definitive end of the "deal winter" that chilled boardrooms for much of the early...

Via MarketMinute

Topics Artificial Intelligence Economy

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Merck & Co (NY:MRK)

All News about Merck & Co

Sections

Services